Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
04 March 2008Website:
http://www.biopathholdings.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
after hours | 81 min agoDividend
Analysts recommendations
Institutional Ownership
BPTH Latest News
Dallas, Texas--(Newsfile Corp. - September 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q2 2024. To view the full announcement, including downloadable images, bios, and more, click here.
Bio-Path (NASDAQ: BPTH ) stock is rising higher on Friday alongside data from the oncology-focused company's Phase 2 clinical trial of prexigebersen. Prexigebersen is Bio-Path product candidate for the targeted treatment of acute myeloid leukemia (AML) alongside decitabine and venetoclax.
Encore Presentation Highlights Positive Results from Interim Analysis Demonstrating Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients Encore Presentation Highlights Positive Results from Interim Analysis Demonstrating Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients
Dallas, Texas--(Newsfile Corp. - June 4, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q1 2024. To view the full announcement, including downloadable images, bios, and more, click here.
Positive Results from Interim Analysis Demonstrate Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients Positive Results from Interim Analysis Demonstrate Significant Clinical Improvement and Tolerable Safety Profile for Prexigebersen Combination in High-Risk Patients
Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML) Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML)
Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML) Presentation Includes Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia (AML)
Bio-Path (BPTH) rises by 30% following positive updates on the progress of its early-stage study of BP1002 for treating acute myeloid leukemia patients.
Shares of Bio-Path (NASDAQ: BPTH) are increasing on Thursday following the company's update on its Phase 1/1b clinical trial of BP1002, which is being studied as a potential treatment for refractory/relapsed acute myeloid leukemia (AML).
Shares of Bio-Path Holdings BPTH, -0.06% fell late Thursday after the company said it had reached a deal for an at-the-market share offering.
What type of business is Bio-Path Holdings?
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.
What sector is Bio-Path Holdings in?
Bio-Path Holdings is in the Healthcare sector
What industry is Bio-Path Holdings in?
Bio-Path Holdings is in the Biotechnology industry
What country is Bio-Path Holdings from?
Bio-Path Holdings is headquartered in United States
When did Bio-Path Holdings go public?
Bio-Path Holdings initial public offering (IPO) was on 04 March 2008
What is Bio-Path Holdings website?
https://www.biopathholdings.com
Is Bio-Path Holdings in the S&P 500?
No, Bio-Path Holdings is not included in the S&P 500 index
Is Bio-Path Holdings in the NASDAQ 100?
No, Bio-Path Holdings is not included in the NASDAQ 100 index
Is Bio-Path Holdings in the Dow Jones?
No, Bio-Path Holdings is not included in the Dow Jones index
When was Bio-Path Holdings the previous earnings report?
No data
When does Bio-Path Holdings earnings report?
Next earnings report date is not announced yet